Genflow widens SIRT6 patent shield with muscular disease program

The latest update is out from Genflow Biosciences Plc ( (GB:GENF) ).

Genflow Biosciences has secured international publication of a Patent Cooperation Treaty application covering variants of the SIRT6 gene for preventing and treating muscular diseases, particularly frailty syndrome and sarcopenia. The filing details compositions and methods using SIRT6-based nucleic acids, polypeptides, vectors and pharmaceutical formulations for conditions involving muscle mass loss and altered muscle endocrine function.

The publication significantly broadens Genflow’s intellectual property around its SIRT6 platform beyond its existing longevity and metabolic focus into muscular indications. This expanded patent scope strengthens the company’s scientific and commercial positioning, preserves its ability to seek protection in multiple jurisdictions, and is expected to support future development flexibility and partnering discussions with pharmaceutical and biotech companies.

Spark’s Take on GENF Stock

According to Spark, TipRanks’ AI Analyst, GENF is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.

To see Spark’s full report on GENF stock, click here.

More about Genflow Biosciences Plc

Genflow Biosciences Plc is a UK-headquartered biotechnology company with R&D facilities in Belgium, focused on developing gene therapies for age-related diseases and healthy ageing. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene and is in a proof-of-concept trial in aged dogs, with additional work exploring its use in treating MASH, a prevalent chronic liver disease lacking effective therapies.

Average Trading Volume: 2,546,548

Technical Sentiment Signal: Buy

Current Market Cap: £10.45M

See more insights into GENF stock on TipRanks’ Stock Analysis page.